Skip to content
Evigrade
MinorEstrogens – natural and semisynthetic×Angiotensin II receptor blocker (ARB, sartan)

Updated · Methodology

Mechanism

CYP3A4 partly metabolises estradiol, so inducers and inhibitors of this enzyme may affect its metabolism (estradiol tablets label, US Food and Drug Administration, FDA). Irbesartan is metabolised in the liver by glucuronide conjugation and oxidation, mainly by CYP2C9, and the contribution of CYP3A4 is negligible (Aprovel SmPC, European Medicines Agency, EMA). Based on in vitro data, no interaction is expected between irbesartan and drugs whose metabolism depends on CYP3A4 (Avapro label, FDA). The irbesartan documents warn about other antihypertensives, drugs that raise potassium, lithium and non-steroidal anti-inflammatory drugs, but not about oestrogens (Aprovel SmPC, EMA; Avapro label, FDA).

Symptoms

The documents describe no symptoms linked to this combination. During hormone replacement therapy, blood pressure sometimes rises slightly, but clinically relevant increases are rare. Oestrogens can cause fluid retention (Progynova SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With volume or sodium depletion, irbesartan can cause symptomatic hypotension, especially after the first dose. It can also raise potassium, especially with renal impairment, overt proteinuria from diabetic nephropathy or heart failure (Aprovel SmPC, European Medicines Agency, EMA).

Management

According to the documents, the doses of estradiol and irbesartan need no change. No document names the pair, and the metabolic pathways of the two drugs do not overlap (Progynova SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; Aprovel SmPC, European Medicines Agency, EMA; estradiol tablets and Avapro labels, US Food and Drug Administration, FDA). Irbesartan is used for hypertension, and hypertension is on the list of conditions that need close supervision in women taking hormone replacement therapy (Progynova SmPC, AEMPS). Blood pressure is monitored at regular intervals during oestrogen use (estradiol tablets label, FDA). If clinically significant sustained hypertension develops during hormone replacement therapy, stopping the therapy is considered, and a significant rise in blood pressure is a reason to stop it immediately (Progynova SmPC, AEMPS). Oestrogens can cause fluid retention, so women with renal or cardiac disorders are closely monitored (Progynova SmPC, AEMPS). When irbesartan is used in renal impairment, serum potassium and creatinine are checked periodically (Aprovel SmPC, EMA). Sodium or volume depletion from diuretics, a salt-restricted diet, diarrhoea or vomiting is corrected before irbesartan is started (Aprovel SmPC, EMA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Estradiol